A new blood-based screening test could significantly improve the detection of aggressive prostate cancer compared with the widely used prostate-specific antigen (PSA) test, according to a new study.
Researchers found that the Stockholm3 test detected 90 percent of clinically significant prostate cancers, compared with 74 percent identified through PSA testing alone, while maintaining a similar rate of false-positive results.
The findings, published in the Annals of Internal Medicine, suggested that the risk-based screening tool could help identify men who need treatment earlier, while reducing unnecessary biopsies.
Prostate cancer is the second most common cancer among men globally.
Although, PSA testing has been the standard screening method for decades, experts explained that elevated PSA levels can also result from non-cancerous conditions such as an enlarged prostate or inflammation, leading to unnecessary scans, biopsies and anxiety.
The Stockholm3 test combines PSA measurements with genetic markers, blood protein biomarkers and clinical information, including
This post was originally published on this site.
